PanTher announced that a methods-of-use patent for a deployable anticancer drug-eluting stent, exclusively licensed to PanTher, has been issued by the USPTO. The patent increases the potential applicability of PanTher’s proprietary Sagittari™ treatment platform, which focuses on direct, localized, and sustained delivery of proven and novel therapeutic agents to attack cancer at the source. PanTher also announced Dan Wildman as a strategic advisor. A seasoned executive with more than 35 years of experience in the MedTech industry, Mr. Wildman previously led the Digital Surgery Strategy initiative at Johnson & Johnson and served as worldwide president of DePuy Synthes Spine and Ethicon Biosurgery.
PanTher Therapeutics Secures Patent for Anticancer Drug-Eluting Stent